Two-step tuberculin skin testing in school-going adolescents with initial 0-4 millimeter responses in a high tuberculosis prevalence setting in South India

PLoS One. 2013 Sep 6;8(9):e71470. doi: 10.1371/journal.pone.0071470. eCollection 2013.

Abstract

Background: The utility of two-step tuberculin skin testing among adolescents in high tuberculosis prevalence settings is not well established.

Objectives: To determine the proportion and determinants of a 0-4 mm response to an initial standard tuberculin skin test (TST) and evaluating 'boosting' with repeat testing.

Methods: Adolescents between 11 and 18 years attending schools/colleges underwent a TST; those with a response of between 0-4 mm had a repeat TST 1-4 weeks later.

Results: Initial TST was done for 6608/6643 participants; 1257 (19%) developed a 0-4 mm response to the initial TST. Younger age and under-nutrition were more likely to be associated with a 0-4 mm response, while the presence of BCG (Bacillus Calmette Guerin) scar and higher socio-economic class were less likely to be associated with a 0-4 mm response. On repeat testing boosting was seen in 13.2% (145/1098; ≥ 6 mm over the initial test) while 4.3% showed boosting using a more conservative cutoff of a repeat TST ≥ 10 mm with an increment of at least 6 mm (47/1098). History of exposure to a tuberculosis (TB) case was associated with enhanced response.

Conclusion: The proportion of adolescents who demonstrated boosting on two-step TST testing in our study was relatively low. As a result repeat testing did not greatly alter the prevalence of TST positivity. However, the two-step TST helps identify individuals who can potentially boost their immune response to a second test, and thus, prevents them from being misclassified as those with newly acquired infection, or tuberculin converters. While two-step tuberculin skin testing may have a limited role in population- level TST surveys, it may be useful where serial tuberculin testing needs to be performed to distinguish those who show an enhanced response or boosters from those who indeed have a new infection, or converters.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • BCG Vaccine / immunology
  • Child
  • Endemic Diseases
  • Female
  • Humans
  • Immunization, Secondary
  • India / epidemiology
  • Male
  • Prevalence
  • Skin / immunology
  • Tuberculin Test
  • Tuberculosis, Pulmonary / epidemiology
  • Tuberculosis, Pulmonary / immunology
  • Tuberculosis, Pulmonary / prevention & control*
  • Vaccination

Substances

  • BCG Vaccine

Grants and funding

The epidemiological study was funded by the Research Council of Norway (GLOBVAC:179342—through the Indo-Norway Programme; Indian partner—Department of Biotechnology) and the Aeras Global TB Vaccine Foundation, USA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.